Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Archive ouverte

Harter, P. | Marth, C. | Mouret-Reynier, M.-A. | Cropet, C. | Lorusso, D. | Lorusso, Domenica | Guerra-Alía, E.M. | Matsumoto, T. | Matsumoto, Takashi | Vergote, I. | Colombo, N. | Mäenpää, J. | Mäenpää, Johanna | Lebreton, C. | de Gregorio, N. | Mosconi, A.M. | Rubio-Pérez, M.J. | Bourgeois, H. | Fasching, P.A. | Cecere, S.C. | Hardy-Bessard, A.-C. | Denschlag, D. | de Percin, S. | Hanker, L. | Favier, L. | Bauerschlag, D. | Desauw, C. | Hillemanns, P. | Largillier, R. | Sehouli, J. | Grenier, J. | Pujade-Lauraine, E. | Ray-Coquard, I. | Bogner, Gerhard | Petru, Edgar | Reinthaller, Alexander | Schauer, Christian | Sevelda, Paul | D’hondt, Lionel | Vuylsteke, Peter | Hietanen, Sakari | Lindahl, Gabriel | Nøttrup, Trine Jakobi | Puistola, Ulla | Abadie-Lacourtoisie, Sophie | Alexandre, Jérôme | Berton-Rigaud, Dominique | Boissier, Emilie | Chevalier-Place, Annick | Combe, Pierre | Costan, Cristina | Dauba, Jérôme | de Cock, Laure | Despax, Raymond | Dohollou, Nadine | Dubot, Coraline | Fabbro, Michel | Floquet, Anne | Follana, Philippe | Tixidre, Claire Garnier | Garnier, Georges | Gladieff, Laurence | Guillemet, Cécile | Hardy-Bessard, Anne-Claire | Joly, Florence | Kalbacher, Elsa | Kaminsky, Marie-Christine | Kurtz, Jean-Emmanuel | Lefeuvre-Plesse, Claudia | Lesoin, Anne | Levache, Charles Briac | L’haridon, Tifenn | Lortholary, Alain | Lotz, Jean-Pierre | Medioni, Jacques | Meunier, Jérôme | Mousseau, Mirerille | Mouret-Reynier, Marie-Ange | Pautier, Patricia | Petit, Thierry | Provansal, Magali | Raban, Nadia | Rodrigues, Manuel | Selle, Frédéric | Sverdlin, Robert | Tazi, Youssef | You, Benoît | Aktas, Bahriye | Olaf Bauerschlag, Dirk | Beck, Thomas | Belau, Antje | Bronger, Holger | Buchholz, Stefan | Buderath, Paul | Burges, Alexander | Canzler, Ulrich | Dieterich, Max | Eichbaum, Michael | El-Balat, Ahmed | Emons, Günter | Feisel-Schwickardi, Gabriele | Frank, Matthias | Friedrich, Michael | Grischke, Eva-Maria | Gropp-Meier, Martina | Hannig, Carla | Hasenburg, Annette | Hellriegel, Martin | Herwig, Uwe | Heubner, Martin | Hulde, Joachim | Jackisch, Christian | Kögel, Matthias | Krieger, Peter | Kühn, Thorsten | Liebrich, Clemens | Lück, Hansjoachim | Mallmann, Peter | Marmé, Frederik | Meier, Werner | Möbus, Voker | Mohamed, Omar Farag | Nestle-Krämling, Carolin | Neunhöffer, Tanja | Oskay-Özcelik, Gülten | Park-Simon, Tjoung-Won | Rautenberg, Beate | Rein, Daniel | Ruhwedel, Wencke | Runnebaum, Ingo | Sagasser, Jacqueline | Schmalfeldt, Barbara | Schneeweiss, Andreas | Schnelzer, Andreas | Scholz, Heinz | Sperfeld, Antje | Steckkönig, Annette | Strauß, Hans-Georg | Tomé, Oliver | Treustedt, Jörn | Voß, Hermann | Wischnik, Arthur | Witteler, Ralf | Wöckel, Achim | Woeltjen, Hans-Heinrich | Zorr, Andreas | Bologna, Alessandra | Tognon, Germana | Cinieri, Saverio | Pignata, Sandro | Savarese, Antonella | Scambia, Giovanni | Sorio, Roberto | Zamagni, Claudio | Fujiwara, Keiichi | Fujiwara, Hiroyuki | Kobayashi, Hiroaki | Nagao, Shoji | Satoh, Toyomi | Yonemori, Kan | Yoshida, Hiroyuki | Bratos, Raquel | Caballero, Cristina | Garica, Yolanda | González-Martín, Antonio | Hernando, Susana | Herrero, Ana | Lainez, Nuria | Manso, Luis | Martin, Cristina | Murata, Eleonor | Ortega, Eugenia | Palacio, Isabel | Poveda, Andres | Romero, Ignacio

Edité par CCSD ; Elsevier -

International audience. The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression in the first-line setting is important to optimize postprogression treatments. We evaluated the efficacy of FST in patients from PAOLA-1/ENGOT-ov25 (NCT02477644) who received first-line olaparib maintenance.

Consulter en ligne

Suggestions

Du même auteur

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Archive ouverte | Pfisterer, Jacobus | CCSD

International audience. State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin-paclitax...

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Archive ouverte | Oaknin, Ana | CCSD

International audience. The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-...

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Lorusso, Domenica | CCSD

International audience. Objective In the PAOLA-1/ENGOT-ov25 trial ( NCT02477644 ), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed...

Chargement des enrichissements...